Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
Prostate Cancer Patients With Bone Metastasis
DRUG: Zoledronic acid
Rate of skeletal complications, 3 months
Time to first skeletal complication, 3 months|Bone pain, 3 months|PatientsÂ´ satisfaction with treatment, 3 months|Bone turnover parameters, 3 months
It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.